| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adicet Bio, Inc.$8.83
-0.11 (-1.23%)
D 30Pipeline Score Richly Valued Pharma · Clinical
Market Cap
75.81 M
EPS
-15.03
P/E Ratio
-0.54 $
Value Trade
892.44 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
17.49 M
Operating CF
-21.49 M
Total Assets
169.38 M
Total Liabilities
29.32 M
Equity
140.06 M
D/E Ratio
12,345
0.61 %
Week
0.97 %
1 Month
13.85 %
3 Month
-10.17 %
6 Month
-96.55 %
5 Year
-99.6 %
All Time
Cash Data
Cash Position
137.59 M
Monthly Burn
7.16 M
Runway
17.2 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
60.80 K
52 Week Range
6.01 - 17.44
% held by Insiders
12.24 %
% held by Institutions
52.04 %
Enterprise Value
-47.88 M
Total Shares
9.58 M
Short %
6.2 %
Float Shares
8.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adicet Bio, Inc.
322Total events
5Upcoming
51Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 5
Event history 317
Q3 2026
◆Timing Guidanceprula-celPresentation
Additional clinical update expected in 2H 2026
autoimmune diseases (LN, SLE, SSc)source ↗
Q3 2026
●IND SubmissionADI-212IND
Regulatory filing for ADI-212 planned in 3Q 2026
metastatic castration-resistant prostate cancer (mCPRC)source ↗
Q3 2026
◆Topline ReadoutADI-212Clinical Data
Initial clinical data for ADI-212 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
Jun 10, 2026
Q2 2026
◆Trial InitiationADI-001Trial
Anticipated initiation of Phase 2 pivotal study in Q2 2026
Lupus Nephritis (LN) and/or Systemic Lupus Erythematosus (SLE)source ↗
Q2 2026
◆Type B Meetingprula-celFDA Meeting
Request FDA meeting in Q2 2026 to inform pivotal trial design
LN or LN and SLEsource ↗
Mar 13, 2026
▲FDA Feedback Receivedprula-celFDA Meeting
FDA alignment enabling outpatient dosing for LN and SLE patients
lupus nephritis (LN) and systemic lupus erythematosus (SLE)source ↗
Feb 12, 2026
◆Oral PresentationPresentation
Adicet Bio to present at Guggenheim Emerging Outlook: Biotech Summit 2026
Q1 2026
◆Timing Guidanceprula-celPresentation
Clinical update expected in 1H 2026
autoimmune diseases (LN, SLE, SSc)source ↗
Drug Pipeline Intelligence
D30
Pipeline Score $5M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 36%
Micro Cap (rank 585 of 912)
Percentile RankAdicet Bio, Inc. faces pipeline headwinds (30/100), with $110M risk-adjusted pipeline value, led by ADI-001 in Rheumatoid Arthritis (RA) (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADI-001 Small molecule | Rheumatoid Arthritis (RA) | Phase 1 | NCT07100873 | 10% | $85M | RECRUITING | 25 | STALLED | C (43) | Mar 30, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
prulacabtagene leucel | autoimmune diseases | Phase 1 | 2026-03-13 | strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the fourth quarter Read More | Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Read More | |
prulacabtagene leucel | autoimmune diseases | Phase 1 | 2026-03-13 | strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the fourth quarter Read More | Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Read More | |
prulacabtagene leucel | autoimmune diseases | Phase 1 | 2026-03-13 | strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the fourth quarter Read More | Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACET
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACET Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACETAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Adicet Bio is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to discuss its strategies and developments in the biopharma sector. Further details regarding the timing and specific topics of discussion have not been disclosed.
Read more →ACETAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio has released its financial results for the first quarter of 2026 along with business updates. The report includes insights into the company's performance and future plans. However, specific details regarding financial figures or strategic initiatives were not disclosed in the article.
Read more →ACETAdicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Adicet Bio reported strong enrollment in its Phase 1 autoimmune program for prulacabtagene leucel, with clinical updates expected in 2026. The company achieved FDA alignment for outpatient dosing in lupus patients. Additionally, a regulatory filing for ADI-212 in metastatic prostate cancer is planned for 2026, with enrollment anticipated to begin later that year.
Read more →ACET▼ -6%on this news
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Adicet Bio, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. CEO Chen Schor will discuss the company's advancements in allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The event will be accessible via a live audio webcast.
Read more →ACETAdicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN)
Adicet Bio has provided a corporate update highlighting important milestones for 2026, including a successful meeting with the FDA to allow outpatient dosing of prulacabtagene leucel for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The company is actively enrolling patients in its Phase 1 autoimmune clinical program, which has expanded to include seven cohorts. Additionally, Adicet plans to submit a regulatory filing for its gene-edited candidate, ADI-212, in 2026, along with further clinical updates expected throughout the year. With a strengthened cash position extending into 2027, Adicet is well-positioned for upcoming pivotal studies.
Read more →ACET▼ -5.4%on this news
Adicet Bio Announces Reverse Stock Split
Adicet Bio, Inc. has announced a one-for-16 reverse stock split to take effect on December 30, 2025. This move aims to help the company regain compliance with Nasdaq's minimum bid price requirement. The split will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, while maintaining the total authorized shares at 300 million.
Read more →ACETAdicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Announced positive preliminary safety and efficacy data from Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) a
Adicet Bio announced positive preliminary safety and efficacy results from its Phase 1 clinical trial of ADI-001 for lupus nephritis (LN) and systemic lupus erythematosus (SLE). The data indicated significant improvements in disease activity and renal function, leading to plans for a pivotal study design meeting with the FDA in early 2026. The company is also actively enrolling patients across various autoimmune diseases for ongoing studies. In addition, Adicet is preparing for a regulatory filing for ADI-212 targeting metastatic castration-resistant prostate cancer and successfully raised $74.8 million in October to support its pipeline.
Read more →ACET▼ -14.7%on this news
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially transformational approa
Adicet Bio has announced positive preliminary data from its Phase 1 study of ADI-001 in patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE). All patients experienced significant reductions in disease activity and improved renal function, indicating the therapeutic effectiveness of ADI-001. The treatment was well tolerated, with no serious adverse events noted. Following these promising results, Adicet plans to meet with the FDA in early 2026 to discuss the design of a pivotal Phase 2 trial set to begin mid-2026.
Read more →ACETAdicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 cli
Adicet Bio reported its financial results for the second quarter of 2025, highlighting active enrollment in multiple clinical trials involving its ADI-001 therapy for autoimmune diseases. The company is on track to share preliminary data in the latter half of 2025 and is also prioritizing the development of ADI-212 for solid tumors. Despite these advancements, Adicet is facing financial pressures, with a reported net loss of $31.2 million, prompting a significant workforce reduction. The company's current cash position is expected to sustain operations through the fourth quarter of 2026.
Read more →ACET▼ -9.4%on this news· ran to -26% by day 1
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary
Adicet Bio reported its financial results for Q1 2025, highlighting ongoing clinical trials and program developments. The company is focused on the Phase 1 trials of ADI-001 for autoimmune diseases and ADI-270 for clear cell renal cell carcinoma, with preliminary data expected in the latter half of 2025. Adicet received Fast Track Designation from the FDA for ADI-001 and has expanded its trial enrollment to include systemic lupus erythematosus patients. However, the company registered a slight increase in its net loss compared to the previous year.
Read more →ACET▼ -8%on this news
Adicet Bio Appoints Michael Grissinger to the Board of Directors --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- REDWOOD CITY, C
Adicet Bio has appointed Michael Grissinger to its Board of Directors, bringing over 40 years of experience in pharmaceutical business development. Grissinger's background includes senior roles at Johnson & Johnson, where he focused on immunology and strategic transactions. His extensive experience could provide valuable insights that may drive Adicet's growth and the development of its gamma delta T cell therapies for treating autoimmune diseases and cancer. The company anticipates that with Grissinger's leadership, its pipeline programs will continue to progress.
Read more →ACETAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data
Adicet Bio has reported its financial results for Q4 and the full year 2024, highlighting ongoing developments in its clinical trials, specifically ADI-001 for autoimmune diseases and ADI-270 for advanced renal cell carcinoma. The company has received Fast Track Designation for ADI-001, underlining the importance of innovative therapies in treating challenging conditions. It anticipates reporting preliminary data from its trials in 2025, with a solid cash position supporting its operational activities. Despite a net loss of $28.7 million in Q4, the company remains focused on advancing its clinical programs.
Read more →ACETAdicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Enrollment underway for patients with metastatic/advanced clear cell renal cell car
Adicet Bio, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial of ADI-270 for patients with metastatic or advanced clear cell renal cell carcinoma (ccRCC). This marks a significant milestone for Adicet as it advances its first gamma delta CAR T cell product candidate targeting one of oncology's highest unmet needs. Positive preclinical data suggests that ADI-270 may demonstrate tumor infiltration and activity against ccRCC. The company expects to present preliminary clinical data in the first half of 2025.
Read more →ACETAdicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials P
Adicet Bio has announced the opening of enrollment for its Phase 1 clinical trial of ADI-270, a gamma delta CAR T cell therapy, in patients with metastatic/advanced clear cell renal cell carcinoma. The trial aims to address the unmet needs in solid tumors that have not benefited from existing CAR T therapies. Preliminary clinical data from this trial is expected to be revealed in the first half of 2025, following a multicenter, open-label study design focused on safety and efficacy. ADI-270 targets CD70-positive cancers, potentially increasing treatment options for patients with aggressive renal cancers.
Read more →ACETAdicet Reports Third Quarter 2024 Financial Results and Provides Business Updates ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephr
Adicet Bio, Inc. reported its financial results for Q3 2024, showcasing a robust expansion of its clinical pipeline, particularly in autoimmune diseases with the ADI-001 Phase 1 trial. The company is now targeting six indications, including lupus nephritis, and anticipates sharing preliminary data in the first half of 2025. Additionally, plans for enrollment in a Phase 1 trial of ADI-270 for metastatic clear cell renal carcinoma are on track. The company maintains a strong balance sheet with over $202 million in cash, allowing them to continue their operations into mid-2026.
Read more →ACET▲ +6.4%on this news
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome ADI-001 clinical development program now addresses six autoimmune diseases Patient enr
Adicet Bio announced that the FDA has granted clearance for an IND amendment to evaluate its therapy, ADI-001, in idiopathic inflammatory myopathy and stiff person syndrome. This regulatory approval expands the ongoing Phase 1 trial to include six autoimmune diseases. Patient enrollment for the new cohorts is expected to begin in the first quarter of 2025, with initial clinical data anticipated in the first half of that year. The company's ongoing efforts reflect a commitment to develop innovative treatments for patients with autoimmune conditions.
Read more →ACETAdicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus
Adicet Bio, Inc. announced the opening of enrollment for its Phase 1 clinical trial of ADI-001, targeting autoimmune diseases such as lupus nephritis. The trial aims to establish the safety and tolerability of this investigational therapy, which has already received FDA Fast Track Designation. Initially, enrollment is open for lupus nephritis patients, while additional conditions like SLE, SSc, and AAV will begin in late 2024. Adicet expects to report preliminary data from the trial in the first half of 2025.
Read more →ACETADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue -Results highlight ADI-001's potential as a best-in-class allogeneic cell therapy for autoi
Adicet Bio, Inc. announced promising results from their Phase 1 GLEAN trial of ADI-001, demonstrating robust tissue trafficking and effective CD19+ B cell depletion in secondary lymphoid tissues. These results suggest that ADI-001 may serve as a best-in-class allogeneic cell therapy for various autoimmune diseases. Further investigation will continue, with initial clinical data expected to be reported in the first half of 2025. The trial's findings highlight ADI-001's efficacy in activating CAR T cells and achieving complete B cell depletion compared to existing therapies.
Read more →ACETAdicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors REDWOOD CITY, Calif. & BOSTON –
Adicet Bio, Inc. has announced the appointment of Lloyd Klickstein, M.D., Ph.D., to its Board of Directors. Dr. Klickstein, who has over two decades of leadership experience in the biopharmaceutical industry, previously held key positions at various organizations, including as the Chief Innovation Officer at Adicet. His expertise is expected to be invaluable for advancing Adicet's programs focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company anticipates that his contributions will enhance their efforts in bringing innovative therapies to patients.
Read more →ACETAdicet Reports Second Quarter 2024 Financial Results and Provides Business Updates ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic scle
Adicet Bio, Inc. has reported its financial results for the second quarter of 2024, highlighting significant advancements in its clinical development programs. The company has expanded its ADI-001 autoimmune therapy's indication from lupus nephritis to include systemic lupus erythematosus, systemic sclerosis, and ANCA-associated vasculitis, following recent FDA IND clearances. Additionally, ADI-270 received IND clearance for renal cell carcinoma and Fast Track Designation, positioning the company favorably for upcoming clinical trials. Despite a net loss for the quarter, Adicet boasts a strong cash position to fund operations through mid-2026.
Read more →ACET▲ +9.3%on this news
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Redwood City, Calif. and BOSTON
Adicet Bio has received Fast Track Designation from the FDA for its investigational therapy ADI-270, aimed at treating patients with metastatic and advanced clear cell renal cell carcinoma who have previously undergone other treatment options. This designation is significant as it highlights the therapy's potential in addressing an unmet medical need in a common type of kidney cancer. ADI-270 is engineered to enhance its effectiveness in targeting CD70-positive tumors, representing a substantial advancement in cancer treatment strategies. The company aims to expedite the development and availability of this innovative therapy to patients in need.
Read more →ACET▲ +9.5%on this news
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical study to evalua
Adicet Bio has received FDA clearance for its IND application to study ADI-270, the first gamma delta 1 CAR T cell therapy candidate aimed at treating relapsed/refractory renal cell carcinoma (RCC). The Phase 1 clinical trial will evaluate the safety and anti-tumor activity of ADI-270, expected to start in the second half of 2024. This development addresses a significant unmet need in RCC treatment, as current options are limited.
Read more →ACET▲ +5.9%on this news
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis Redwood City, Calif. and BOSTON
Adicet Bio has announced that the FDA has granted Fast Track Designation to its investigational drug ADI-001 for the treatment of relapsed/refractory class III or IV lupus nephritis. This designation highlights the urgent medical need for effective therapies in this chronic condition. The company plans to commence Phase 1 clinical trials later this month, which are intended to validate ADI-001's therapeutic potential. Furthermore, Adicet aims to expand its autoimmune program to address additional indications beyond lupus nephritis. The announcement signals a significant step forward in Adicet's clinical pipeline and commitment to treating autoimmune diseases.
Read more →ACET▼ -7.6%on this news
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-2
Adicet Bio reported strong financial results for Q1 2024, highlighting plans to initiate a Phase 1 clinical trial for ADI-001 targeting lupus nephritis in the second quarter. The company also presented encouraging preclinical data on ADI-270 at a major conference, showcasing its potential in treating various cancers. With a solid cash balance of $247.6 million, Adicet is well-positioned to support its ongoing and future clinical trials. However, pressures from net losses and the inherent unpredictability of trial outcomes pose risks to their strategy.
Read more →ACET▼ -9.8%on this newsshared move
ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Candidate Designed for Multiple Solid and Hematological Cancer Indications 27th ASGCT Annual Meeting 2024 Baltimore, MD Shon Green, PhD VP, Noncl
ADI-270, an armored allogeneic anti-CD70 CAR T cell therapy, was presented at the 27th ASGCT Annual Meeting. This therapy targets various refractory cancers, including solid and hematological malignancies, and exhibited promising anti-tumor activity in xenograft models. It demonstrated resilience to inhibitory tumor microenvironment factors like TGF and showed significant cytotoxicity against tumors with varying CD70 expression. Adicet Bio plans to submit an Investigational New Drug application for ADI-270 in clear cell renal cell carcinoma in the second quarter of 2024.
Read more →ACETAdicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Preclinical findings showed robust anti-tum
Adicet Bio announced promising preclinical data for ADI-270, an allogeneic CAR T cell therapy targeting CD70 positive tumors. The findings demonstrate strong anti-tumor effects across multiple cancer models, indicating its potential effectiveness. An oral presentation to share these results is scheduled for May 10, 2024, at the ASGCT annual meeting, where the company will also discuss its plans to file an IND application in the second quarter of 2024. ADI-270's innovative design offers enhanced functional potency and resilience in tumor microenvironments, positioning it favorably for clinical development.
Read more →ACETAdicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Inve
Adicet Bio reported its financial results for Q4 and the full year 2023, highlighting recent developments in its clinical pipeline. The FDA granted IND clearance for ADI-001, aiming to initiate a Phase 1 study for lupus nephritis in Q2 2024. The company has also extended its cash runway into the second half of 2026 following a successful capital raise. However, Adicet experienced a net loss of $142.7 million for the year and reported a significant goodwill impairment.
Read more →ACETAdicet Bio, Inc. Announces Proposed Public Offering REDWOOD CITY, Calif. & BOSTON
Adicet Bio, Inc. has announced a proposed public offering of its common stock and pre-funded warrants to raise funds for its development of gamma delta T cell therapies. The offering is underwritten by Jefferies and Guggenheim Securities, with a 30-day option for underwriters to purchase additional shares. While this move reflects the company's ambition to finance its clinical developments, it is subject to market conditions, which introduces potential uncertainties about completion and terms.
Read more →ACET▼ -9.9%on this news· ran to -27% by day 3
Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer
Adicet Bio, Inc. is progressing with the clinical development of its allogeneic CAR gamma delta T cell therapies, specifically ADI-001 and ADI-270, aimed at treating autoimmune diseases and cancers. The company plans to initiate a Phase 1 trial of ADI-001 in lupus nephritis in the second quarter of 2024 and has expressed optimistic expectations regarding clinical trial updates. However, the success of these initiatives is subject to various risks, including regulatory approval timelines and the predictability of clinical outcomes. Overall, Adicet is focused on addressing unmet needs in the treatment of B-cell mediated autoimmune disorders and expanding its therapeutic pipeline.
Read more →ACET▲ +22.7%on this news· ran to +96% by day 3
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to
Adicet Bio has provided an update on its strategic priorities for 2024, focusing on expanding the clinical development of its gamma delta T cell therapies. The company announced the clearance of the IND for its investigational product ADI-001 in lupus nephritis and plans to initiate a Phase 1 clinical trial in this area in the second quarter of 2024. Meanwhile, Adicet will focus patient enrollment on mantle cell lymphoma in an ongoing trial, reporting positive preliminary results. The company also anticipates filing an IND for another product, ADI-270, for renal cell carcinoma within the same timeframe.
Read more →ACETAdicet Reports Third Quarter 2023 Financial Results and Provides Business Updates Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle
Adicet Bio, Inc. announced its third quarter financial results and business updates, highlighting the initiation of the ADI-001 Phase 1 EXPAND cohort for treating post CAR T large B cell lymphoma. The company is also continuing to enroll patients for mantle cell lymphoma in its Phase 1 study of ADI-001. Additionally, Adicet plans to prioritize the development of ADI-270 for solid tumors, targeting a submission for an Investigational New Drug Application in the first half of 2024. Despite advancements in its clinical pipeline, Adicet faced significant financial losses, including a goodwill impairment.
Read more →ACETAdicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory
Adicet Bio, Inc. reported its financial results for the second quarter of 2023, highlighting significant progress in its clinical studies. The company announced favorable safety and efficacy data from its Phase 1 trial of ADI-001 for treating relapsed or refractory B-cell non-Hodgkin's lymphoma. Adicet also revealed plans for new Investigational New Drug Applications for ADI-925 and ADI-270, while maintaining a solid cash position of $205.5 million. However, the company recorded a net loss of $32.4 million, marking an increase from the previous year.
Read more →ACETAdicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif. & BOSTON –
Adicet Bio, Inc. has appointed Katie Peng to its Board of Directors, aiming to leverage her extensive industry experience as the company advances its pipeline of allogeneic gamma delta T cell therapies, particularly ADI-001. Ms. Peng brings a robust background in commercial leadership, previously overseeing significant oncology and rare disease portfolios while at Denali Therapeutics and Genentech. Her involvement is expected to be valuable as Adicet prepares for a pivotal study in post CAR T large B-cell lymphoma and aims for future commercialization of its therapies.
Read more →ACETAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) ADI-001 demonstrated 71% overall response rate (ORR) and 63% comp
Adicet Bio has reported promising results from its Phase 1 trial of ADI-001 for treating relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. The therapy showed a 71% overall response rate and a 63% complete response rate, with particularly high efficacy in heavily pre-treated patients. With a favorable safety profile and plans for a pivotal Phase 2 study in 2024, these findings indicate significant potential for ADI-001 in addressing an unmet medical need in this patient population. Further updates are expected as the trial progresses.
Read more →ACETAdicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting ADI-270 includes Adicet's proprietary armoring technology and enhancements designed fo
Adicet Bio has presented promising preclinical data for its ADI-270 therapy at the ASGCT annual meeting. This allogeneic gamma delta CAR T cell therapy, targeting CD70+ cancers, showcased significant anti-tumor activity and resilience against immune targeting. Notably, ADI-270 exhibits enhanced persistence in solid tumors, suggesting potential for better clinical outcomes.
Read more →ACETAdicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in
Adicet Bio, Inc. reported its first quarter 2023 financial results, highlighting ongoing progress with its lead asset ADI-001. The company plans to discuss the path for a pivotal study with the FDA and report updated trial data in the second quarter. Financially, Adicet has $231.6 million in cash, although it faced a net loss of $30.9 million. The company also shared promising preclinical data for ADI-270 and plans to submit an Investigational New Drug Application for ADI-925 later this year.
Read more →ACETAdicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress • Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatme
Adicet Bio, Inc. reported its fourth-quarter and full-year financial results for 2022, highlighting key operational developments. The company announced positive interim safety and efficacy results for its ADI-001 therapy targeting relapsed or refractory B-cell non-Hodgkin's lymphoma. As it continues to advance its clinical trials, Adicet plans to discuss pivotal study designs with the FDA in the upcoming quarter. However, the company experienced a significant increase in net loss and research and development expenses during the reporting period.
Read more →ACETAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) ADI-001 demonstrated 75% overall response rate (ORR) and 69% comp
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable sa
Read more →ACETVirtual R&D Event
Virtual R&D Event November 10, 2022 Forward-Looking Statements This presentation contains forward-looking statements of Adicet Bio, Inc. (Adicet) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet. These forwa
Read more →ACETAdicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut fro
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual Meeting Comp
Read more →ACETAdicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) As of the
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete response rate and sustained durabi
Read more →ACETAdicet Reports Second Quarter 2022 Financial Results and Provides Business Updates ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL, as of May 31, 2022 da
Read more →ACETAdicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerabili
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade
Read more →ACETAdicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) As of the
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a f
Read more →ACETAdicet Reports First Quarter 2022 Financial Results and Provides Business Updates Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9million
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9million in cash and cash equivalents as of MENLO PARK, Calif. an
Read more →ACETAdicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Ma
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies ADI-001 exhibited robust in vitro and in vivo tu
Read more →ACETAdicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001 Menlo Park, CA and Boston, MA –
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001 Menlo Park, CA and Boston, MA April 19, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen recept
Read more →ACET▲ +5.5%on this news· ran to +31% by day 3
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress • Complete and near complete responses observed starting at lowest dose in interim findings from Phase 1 st
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress -Complete and near complete responses observed starting at lowest dose in interim findings from Phase 1 study of ADI-001 in non-Hodgkin's lymphoma (NHL); additional interim
Read more →ACETAdicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously
Read more →ACET▲ +5.5%on this newsshared move
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritte
Read more →ACET▲ +6.8%on this newsshared move
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock MENLO PARK, Calif. and
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock MENLO PARK, Calif. and BOSTON, Mass., December 7, 2021 (GLOBE NEWSWIRE) Adicet Bio, Inc. ( Adicet ) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies f
Read more →ACET▲ +38.5%on this newsshared move
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma (ORR=75%, CR=50%) No ADI-001-related serious adverse events, including GvHD, neurotoxicity or high-grade CRS have been rep
Read more →ACETAdicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology
Read more →ACETAdicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA –
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA November 18, 2021 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer
Read more →ACETAbout Adicet Bio, Inc. Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting Adicet's allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate an
Read more →ACETAdicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
Adicet’s allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company’s gamma delta T cell platform Preclinical findings demonstrated potent gamma
Read more →ACETAdicet Reports Third Quarter 2021 Financial Results and Provides Business Updates  On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end &
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end Announced collaboration with Twist Bioscience to accelerate discover
Read more →ACETAdicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Exe
Read more →ACETAdicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that a Trials in Progress abs
Read more →ACETAdicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been
Read more →ACETAdicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data
Read more →ACETAdicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics MENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif. –
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics MENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif. September 13, 2021 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and develop
Read more →ACETAdicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in
Read more →ACETAdicet Reports Second Quarter 2021 Financial Results and Provides Business Updates On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 Menlo Park, CA and
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 Menlo Park, CA and Boston, MA August 12, 2021 Adicet Bio, Inc. (Nasdaq: ACET
Read more →ACETAdicet Bio Announces Formation of Scientific Advisory Board
MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the formation of a Scientific Advisory Board
Read more →ACETAdicet Bio Added to the Russell 2000 Index
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company has been added to the Russe
Read more →ACETBalance Sheet Data (in thousands) (unaudited)
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates Menlo Park, CA and Boston, MA - May 17, 2021 - Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer
Read more →ACETAdicet Reports First Quarter 2021 Financial Results and Provides Business Updates
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021 Successfully raised $143.8 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gam
Read more →ACETAdicet Bio to Participate in Fireside Chat at the 7th Annual Truist Securities Life Sciences Summit
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer
Read more →ACETAdicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer
Read more →ACETAdicet Bio Appoints Dr. Blake Aftab as Vice President of Research
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as V
Read more →ACETAdicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Menlo Park, CA and Boston, MA March 11, 2021 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an
Read more →ACETAdicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin s Lymphoma Company s lead candidate, ADI-001, is believed to be the first IND-cleared allogeneic CAR
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin s Lymphoma Company s lead candidate, ADI-001, is believed to be the first IND-cleared allogeneic CAR gamma-delta T cell therapy to reach human trials MEN
Read more →ACETAdicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors MENLO PARK, CA and BOSTON, MA
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors MENLO PARK, CA and BOSTON, MA March 04, 2021 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announ
Read more →ACETAdicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the closing of an underwri
Read more →ACETAdicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement
MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the pricing of an underwritten pu
Read more →ACETAdicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement MENLO PARK, Calif. and BOSTON
Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement MENLO PARK, Calif. and BOSTON, February 09, 2021 (GLOBE NEWSWIRE) Adicet Bio, Inc. ( Adicet ) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma
Read more →ACETAdicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Exe
Read more →ACETAdicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors Menlo Park, CA and Boston, MA
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors Menlo Park, CA and Boston, MA December 1, 2020 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and o
Read more →ACETAdicet Reports Third Quarter 2020 Financial Results and Provides Business Update Menlo Park, CA and Boston, MA
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update Menlo Park, CA and Boston, MA November 5, 2020 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer a
Read more →ACETEMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made between Adicet Therapeutics, Inc., a Delaware corporation (the Company ), and Don Healey (the Executive ) and is dated as of
EMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made between Adicet Therapeutics, Inc., a Delaware corporation (the Company ), and Don Healey (the Executive ) and is dated as of September 24, 2020. WHEREAS, the Company desires to employ the Executive and the E
Read more →ACETAdicet Appoints Don Healey, Ph.D., as Chief Technology Officer
MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey
Read more →ACETAdicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy - Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin s lymp
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy Park, CA and Boston, MA October 22, 2020 Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo
Read more →ACETAdicet Bio to Present at the Jefferies Cell Therapy Summit
MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executi
Read more →ACETAdicet Bio, Inc. Determines Not to Proceed with Public Offering of Common Stock
MENLO PARK, Calif. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced today that it has determined not to proceed with
Read more →ACETAdicet Bio, Inc. Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif. and BOSTON, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has commenced an underwr
Read more →ACETAdicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
MENLO PARK, Calif. and BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020, the
Read more →ACETMANAGEMENT FOLLOWING THE MERGER Executive Officers and Directors of the Combined Company Following the Merger Following the merger, the resTORbio Board is expected to consist of seven directors. Pursuant to the merger ag
MANAGEMENT FOLLOWING THE MERGER Executive Officers and Directors of the Combined Company Following the Merger Following the merger, the resTORbio Board is expected to consist of seven directors. Pursuant to the merger agreement, all of the current directors of resTORbio, other
Read more →ACETAdicet Announces Completion of Merger with resTORbio - Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on
Adicet Announces Completion of Merger with resTORbio - Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol ACET - Menlo Park, CA and Boston,
Read more →ACETAdicet Bio Appoints Nick Harvey as Chief Financial Officer
MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Nick Harvey as Chief Fi
Read more →ACETForward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: future p
Allogeneic Gamma Delta T Cells Engineered to Fight Cancer September 16, 2020 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited t
Read more →ACETAdicet Bio to Present at the Cantor Virtual Global Healthcare Conference
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Office
Read more →ACETresTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results BOSTON, Massachusetts, July 30, 2020 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or
Read more →ACETForward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the exp
resTORbio and Adicet Bio July 28, 2020 Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the expected structure, ti
Read more →ACETthis press release which are not strictly historical statements, including, without limitation, our expectations of the potential impact of COVID-19 on strategy, future operations, and the timing of our clinical trials,
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents Boston, MA, May 28, 2020 - resTORbio, Inc. (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-con
Read more →ACETresTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results BOSTON, Massachusetts, May 07, 2020 - resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or tr
Read more →ACETresTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology Combined Company to Focus on Adicet s Technology and Continue Operations as Adicet Bio Adicet s lead asse
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology Combined Company to Focus on Adicet s Technology and Continue Operations as Adicet Bio Adicet s lead asset ADI-001 is an allogeneic gamma delta T cell therapy exp
Read more →ACETresTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update BOSTON, Massachusetts, March 12, 2020 - resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging
Read more →ACETForward-looking statements This presentation has been prepared by resTORbio, Inc. ("we," "us," "our," "resTORbio," or the "Company") and is made for informational purposes only and does not constitute an offer to sell or
Targeting the biology of aging to treat aging-related diseases Corporate Presentation February 2020 Exhibit 99.1 Forward-looking statements This presentation has been prepared by resTORbio, Inc. ("we," "us," "our," "resTORbio," or the "Company") and is made for informational p
Read more →ACETThis presentation has been prepared by resTORbio, Inc. ("we," "us," "our," "resTORbio," or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer
November 2019 Guggenheim Healthcare Talks Neuro/Immunology Day Exhibit 99.1 This presentation has been prepared by resTORbio, Inc. ("we," "us," "our," "resTORbio," or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solic
Read more →ACETresTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint Company stops further development of clinically symptomatic respiratory ill
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in ot
Read more →ACETresTORbio Reports Third Quarter 2019 Financial Results and Corporate Update Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek 2019 BOSTON, Massachusetts,
Read more →ACETresTORbio Reports Second Quarter 2019 Financial Results and Corporate Update - Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quart
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update - Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 - BOSTON, MA, August 14, 2019 - resTORbio, Inc.
Read more →ACETresTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness Company plans to announce topline data from PROTECTOR 1 by early first quarter of
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 PROTECTOR 2 is planned to start in the fourth quarte
Read more →ACETresTORbio Reports First Quarter 2019 Financial Results and Corporate Update Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 tria
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of RTB
Read more →ACETresTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness Top-line data from both PROTECTOR Phase 3 studies expected in mid-2020
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness Top-line data from both PROTECTOR Phase 3 studies expected in mid-2020 BOSTON, Massachusetts, May 9, 2019 resTORbio, Inc. (Nasdaq: TORC), today announced the init
Read more →ACETresTORbio, Inc. Announces Pricing of Public Offering of Common Stock
resTORbio, Inc. Announces Pricing of Public Offering of Common Stock Massachusetts, March 19, 2019 (GLOBE NEWSWIRE) resTORbio, Inc. ( resTORbio or the Company ) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of
Read more →ACETresTORbio Reports Fourth Quarter and Full Year 2018 Financial Results Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a t
resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson'
Read more →ACETThis presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulato
March 2019 Targeting the biology of aging to prevent and treat aging-related diseases Exhibit 99.1 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements r
Read more →ACETresTORbio Reports Third Quarter 2018 Financial Results Additional positive data from Phase 2b trial further support RTB101's potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly
resTORbio Reports Third Quarter 2018 Financial Results Additional positive data from Phase 2b trial further support RTB101's potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients Initiation of pivotal Phase 3 program of RTB101
Read more →ACETresTORbio Appoints Michael Grissinger to its Board of Directors - Brings extensive business development and licensing experience to resTORbio s Board - BOSTON
resTORbio Appoints Michael Grissinger to its Board of Directors - Brings extensive business development and licensing experience to resTORbio s Board - BOSTON, November 6, 2018 resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people
Read more →ACETRESTORBIO, INC. EMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made as of the 30th day of August, 2018, between resTORbio, Inc., a Delaware corporation (the Company ), and Meredith S. Manning (the Execut
EMPLOYMENT AGREEMENT This Employment Agreement ( Agreement ) is made as of the 30th day of August, 2018, between resTORbio, Inc., a Delaware corporation (the Company ), and Meredith S. Manning (the Executive ) and is effective as of September 17, 2018 (the Effective Date ). NO
Read more →ACETresTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors Brings extensive experience in clinical and pipeline development to resTORbio s Board BOSTON
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors Brings extensive experience in clinical and pipeline development to resTORbio s Board BOSTON, August 15, 2018 resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping pe
Read more →ACETresTORbio Reports Second Quarter 2018 Financial Results -- Phase 2b results identify dose and patient population for pivotal program with RTB101 -- -- Initiation of pivotal program with RTB101 expected in the first half
resTORbio Reports Second Quarter 2018 Financial Results -- Phase 2b results identify dose and patient population for pivotal program with RTB101 -- -- Initiation of pivotal program with RTB101 expected in the first half of 2019 -- BOSTON, Massachusetts, August 9, 2018 - resTOR
Read more →ACETresTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101 Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101 Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), the primary endpoint of the tria
Read more →ACETresTORbio Reports First Quarter 2018 Financial Results Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018
resTORbio Reports First Quarter 2018 Financial Results Last patient dosed in Phase 2b trial; topline data now expected in third quarter of 2018 BOSTON, Massachusetts, May 10, 2018 - resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping peo
Read more →ACETresTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly Topline 16-week data now expected in the third quarter of 2018
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly Topline 16-week data now expected in the third quarter of 2018 BOSTON, Massachusetts, May. 9, 2018 resTORbio, Inc. (NASDAQ:TORC), a clinical-stage b
Read more →ACETresTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results Massachusetts, Mar. 29, 2018 resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel th
Read more →Competitive Position
How ACET ranks across every disease it competes inCompetitive Position is a premium feature
See how ACET ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial